Trending Topic

Human Internal Digestive Organs Pancreas with Gallbladder Anatomy
17 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Article Highlights Early use of sodium–glucose co-transporter-2 inhibitors following myocardial infarction was associated with the following factors: Lower hospitalization for heart failure (odds ratio [OR]: 0.75; 95% confidence interval [CI]: 0.62–0.90; p=0.002). Similar cardiovascular deaths (OR: 1.04; 95% CI: 0.83–1.30; p=0.76). Similar all-cause mortality (OR: 1.00; 95% CI: 0.82–1.21; p=0.98). Similar risks of ketoacidosis, acute […]

Arun Sanyal, EASL ILC 2021: Icosabutate ICONA Trial in NASH

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 1st 2021

In Part 2, we speak with Prof. Arun Sanyal (Virginia Commonwealth University, Richmond, VA, USA) about the interim analysis from the ICONA trial (NCT04052516) which is designed to investigate icosabutate as a potential therapeutic approach to address liver- and cardiovascular-related morbidity and mortality in patients with NASH.

His abstract entitled ‘Icosabutate, a novel structurally engineered fatty acid, significantly reduces relevant markers of NASH and fibrosis in 16 weeks: interim analysis results of the ICONA trial’ was presented at the International Liver Congress (ILC) 2021, 23-26 June.

Please view Part 1 for information on the mechanism of action of icosabutate.

Disclosures: Prof Arun Sanyal has acted as an advisor/board member for Gilead; a consultant for 89 BIO, Affimune, Albireo, Allergan, AMRA, Ardelyx, BASF, Birdrock, Boehringer Ingelheim, Bristol Myers Squibb, Chemomab, Conatus, Durect, Echosans, Enyo, Fractyl, Galectin, General Electric, Genfit, Gilead Hemoshear, Immuron, Indalo, Intercept, Janssen, Lilly, Malinckrodt, Merck, Nimbus, Novartis, Northsea, Novo Nordisk, Perspectum, Pfizer, Poxel, Salix, Sanofi, Second Genome, Servier, Takeda, Terns, Teva, Zydus; received grant/research support from Bristol-Myers Squibb, Conatus, Echosans, Galectin, Gilead, Lilly, Malinckrodt, Merck, Novartis, Novo Nordisk, Fractyl, Madrigal, Inventiva, Covance and Sequana; has stockholder/ownership interest (excluding diversified mutual funds) in Akarna, Durect, Exhalenz, Genfit, Hemoshear, Indalo, Tiziana; is PI for an ongoing trial sponsored by Genfit; has provided advice (no remuneration) to BASF, Galectin, Immuron and has received Royalties from Elsevier and UpToDate.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.

Filmed in coverage of the EASL ILC 2021, 23-26 June.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup